FDA Approvals
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.).
Learn More
On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.)
Learn More
On April 26, 2024, the Food and Drug Administration issued three draft guidance documents on eligibility criteria in cancer clinical trials to address performance status, washout periods and concomitant medications, and laboratory values.
Learn More
On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]).
Learn More
National Guideline Updates
Check out the NCCN Calendar of Events:
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Esophageal and Esophagogastric Junction Cancers.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hairy Cell Leukemia
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Biliary Tract Cancers to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers v1.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma v3.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Non-Small Cell Lung Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v5.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Rectal Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer v1.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for T- Cell Lymphomas to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for T-Cell Lymphomas v3.2024
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for T-cell Large Granular Lymphocytic Leukemia and T-Cell Prolymphocytic Leukemia to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for T-Cell Lymphomas V.3.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Multiple Myeloma to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma v3.2024.
Learn More
Coding and Reimbursement Updates
View E-Reimbursement Newsletter Here
Learn More
Other
On April 10, 2024 Takeda Announces EXKIVITY (mobocertinib) Is No Longer Commercially Available in U.S. Market.
Learn More
View Noridian Medicare Jurisdiction E Part B Updates.
Learn More
